Authors

Latest:

Nodule Size Should Not Determine Biopsy Decision in Thyroid Cancer

The recent American Thyroid Association guidelines to abstain from cytological evaluation by biopsy for patients with thyroid cancer on the basis of having thyroid nodules â‰¤1 cm is not advisable.

W. Todd Penberthy, PhD

Latest:

Coexisting BRAF/TERT Mutations Predict Aggressive Thyroid Cancer

Coexisting mutations in BRAF and TERT may be associated with an aggressive phenotype and higher recurrence rates for patients with locally advanced well-differentiated thyroid cancers.

W. Victoria Lai, MD

Latest:

Dr. Lai on the Results of the CASPIAN Trial in Small Cell Lung Cancer

W. Victoria Lai, MD, discusses the results of the phase III CASPIAN trial in small cell lung cancer.

W. Zhao, MD, MS

Latest:

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.

Wade T. Iams, MD

Latest:

Insights from ARTEMIS-001

Panelists discuss how preliminary results from the pPhase 3 ARTEMIS-001 study indicate that iIfinatamab dDeruxtecan, a B7-H3 antibody-drug conjugate, demonstrates promising antitumor activity in relapsed small cell lung cancer, with a notable partial response rate and manageable safety profile among treated patients.

Wafik El-Deiry, MD, PhD, FACP

Latest:

Dr. El-Deiry on Liquid Vs Tissue Biopsies

Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses the advantages of liquid biopsies over tissue biopsies.

Wafik S. El-Deiry, MD, PhD, FACP

Latest:

It's Not Quite Prime Time for Up-Front Genomic Sequencing in Early-Stage CRC

Although testing for some genetic defects has been incorporated into the treatment paradigm, the clinical utility of up-front tumor sequencing that would yield wide-ranging information has not yet been established.

Wallace L. Akerley, MD

Latest:

Dr. Akerley on MET Biomarker in Lung Cancer

Wallace L. Akerley, MD, discusses using MET as a biomarker in lung cancer.

Walter Curran, JR., MD, FACR, Winship Cancer Institute of Emory University

Walter J. Curran, Jr., MD

Latest:

Dr Curran on Developing Strategies for Stage III NSCLC Management

Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.

Walter J. Curran, Jr, MD, FACR, FASCO

Latest:

Dr. Curran on the Integration of Immunotherapy With Radiation Therapy in Lung Cancer

Walter J. Curran, Jr, MD, FACR, FASCO, explains the eligibility criteria for immunotherapy and radiation in patients with lung cancer.

Walter M. Stadler, MD

Latest:

Dr Stadler on Enhancing Diversity in Early Phase Clinical Trials For Underserved Communities

Walter M. Stadler, MD, discusses his role within the Stand Up To Cancer® 4-team initiative, where he will aim to enhance diversity in early-phase clinical trials in underserved urban community.

Walter Rayford, MD, PhD, MBA

Latest:

Dr. Rayford on the Racial Genomics of Prostate Cancer

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses the racial genomics of prostate cancer.

Walter Stadler, MD, University of Chicago

Warner K. Huh, MD, UAB

Latest:

Cervical Cancer Management: Looking Toward the Future of Care

Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.

Wassim Abida, MD, PhD

Latest:

Dr. Abida on Future Research Directions in mCRPC

Wassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.

Waun K. Hong, MD

Latest:

Dr. Hong on Advances in Head and Neck Cancer

Waun K. Hong, MD, FACP, DMSc, division head, American Cancer Society Professor, Samsung Distinguished University Chair in Cancer Medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and 2018 Giant of Cancer Care® in Head and Neck Cancer, discusses advances in the treatment of patients with head and neck cancer.

Wayne A. Bardwell, PhD, MBA

Latest:

Dr. Bardwell Expresses the Importance of Listening

Dr. Wayne Bardwell from UCSD Cancer Center Expresses the Importance of Listening

Wayne A. Marasco, MD, PhD

Latest:

Dr. Marasco on Engineering CAR T Cells

Wayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.

Wayne Kuznar

Latest:

Lenalidomide/Rituximab Regimens Show Encouraging Responses in Relapsed/Refractory Follicular Lymphoma, But Slow Accrual Axes Study

The regimen of lenalidomide in combination with rituximab with bendamustine are effective therapies for relapsed/refractory follicular lymphoma, with high rates of overall and complete metabolic response by PET, according to data from the randomized phase 2 HOVON110/Rebel trial.